title: Molecular response to first line nilotinib in a patient with e19a2 BCR-ABL1 chronic myeloid leukemia.
authors.forename: Stephen E
authors.initials: SE
authors.lastname: Langabeer
authors.forename: Sarah L
authors.initials: SL
authors.lastname: McCarron
authors.forename: Peig
authors.initials: P
authors.lastname: Carroll
authors.forename: Johanna
authors.initials: J
authors.lastname: Kelly
authors.forename: Michael
authors.initials: M
authors.lastname: O'Dwyer
authors.forename: Eibhlin
authors.initials: E
authors.lastname: Conneally
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D054316:Biomarkers, Pharmacological / Q000032:analysis; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis* / Q000188:drug therapy* / Q000235:genetics*; D025202:Molecular Diagnostic Techniques; D020360:Neoadjuvant Therapy; D011743:Pyrimidines / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D054316:Biomarkers, Pharmacological; D011743:Pyrimidines; C498826:nilotinib